Opinion|Videos|October 7, 2024
Latest Advances and Therapies for HER2+ NSCLC
Key Takeaways
- Emerging HER2-directed therapies show promise in NSCLC, with significant results from SOHO-01, inetetamab/pyrotinib, and Beamion LUNG-1 studies.
- These studies indicate a potential shift in the treatment landscape, offering new options for patients with HER2 mutations in NSCLC.
Panelists discuss how recent clinical trial results for emerging HER2-directed therapies, including findings from the SOHO-01 study, inetetamab/pyrotinib combination study, and Beamion LUNG-1, are shaping the future landscape of NSCLC treatment, while also highlighting other noteworthy developments presented at this year’s World Conference on Lung Cancer.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Several HER2-directed therapies are currently in development. Could you discuss the recent clinical trial results for emerging agents, such as those from the SOHO-01 study, the inetetamab/pyrotinibcombination study, and the Beamion LUNG-1 study, and what implications these findings might have for the future landscape of HER2-directed therapies in NSCLC?
- (Heymach) What other notable data from this year’s World Conference on Lung Cancer are you most excited about?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Cytokines Linked With Drug Resistance in Ovarian Cancer, but Underlying Mechanisms Remain Unclear
2
Mepolizumab Reduces Health Care Resource Utilization, Work Impairment in Severe Asthma
3
FDA Expands Sotatercept Indication for PAH
4
CHEST 2025 Highlights: Future of Respiratory Vaccines and the Impact of Federal Funding Cuts
5
